Inositol safety: clinical evidences.

Article Details

Citation
Copy to clipboard

Carlomagno G, Unfer V

Inositol safety: clinical evidences.

Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):931-6.

PubMed ID
21845803 [ View in PubMed
]
Abstract

Myo-inositol is a six carbon cyclitol that contains five equatorial and one axial hydroxyl groups. Myo-inositol has been classified as an insulin sensitizing agent and it is commonly used in the treatment of the Polycystic Ovary Syndrome (PCOS). However, despite its wide clinical use, there is still scarce information on the myo-inositol safety and/or side effects. The aim of the present review was to summarize and discuss available data on the myo-inositol safety both in non-clinical and clinical settings. The main outcome was that only the highest dose of myo-inositol (12 g/day) induced mild gastrointestinal side effects such as nausea, flatus and diarrhea. The severity of side effects did not increase with the dosage.

DrugBank Data that Cites this Article

Drugs